The monitoring of heparin administration by screening tests in experimental dogs

Research in Veterinary Science

Volumn 70, Issue 2, 2001, Pages 101-108

  Mischke, R ^a   Jacobs, C ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; HEPARIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING TEST; CONTROLLED STUDY; DOG; DOSE CALCULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; FEMALE; HEMOSTASIS; INTERMETHOD COMPARISON; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; SCREENING TEST; THROMBIN TIME; TREATMENT PLANNING;

CANIS FAMILIARIS;

EID: 0034981287     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1053/rvsc.2000.0447     Document Type: Article

References (26)

1. ANDERSSON, L.-O., BARROWCLIFFE, T. W., HOLMER, E., JOHNSON, E. A. & SODERSTROM, G. (1979) Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thrombosis Research 15, 531-541
2. BAKER, B. A., ADELMAN, M. D., SMITH, P. A. & OSBORNE, J. C. (1997) Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Archives of internal Medicine 157, 2475-2479
3. BARZU, T., VAN RIJN, J. L., PETITOU, M., TOBELEM, G. & CAEN, J. P. (1987) Heparin degradation in endothelial cells. Thrombosis Research 47, 601-609
4. BHARGAVA, A. S., SCHOEBEL, C. H. R. & GUNZEL, P. (1981) Characterization of a new potent heparin. Arzneimittel-Forschung/Drug Research 30, 79-82
5. BRILL-EDWARDS, P. GINSBERG, J. S., JOHNSTON, M. & HIRSH, J. (1993) Establishing a therapeutic range for heparin therapy. Annals of Internal Medicine 119, 104-109
6. D'ANGELO, A., SEVESO, M. P., D'ANGELO, S. V., GILARDONI, F., DETTORI, A. G. & BONINI, P. (1990) Effect of clot-detection methods and reagents on activated partial thromhoplastin time (APTT). Implications in heparin monitoring by APTT. American Journal of Clinical Pathology 94, 297-306
7. GREEN, R. A. (1980) Activated partial thromboplastin time in monitoring heparinized dogs. American Journal of Veterinary Research 11, 1793-1797
8. HARTERT, H. (1984) Biorheology in the practice of medicine: resonance thrombography. Biorhology 21, 19-32
9. HELLEBREKERS, L. J., SLAPPENDEL, R. J. & VAN DEN BROM, W. E. (1985) Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. American Journal of Veterinary Research 46, 1460-1462
10. HINSENBROCK, K. P., ANDERS, O., ERNST, B., NEUMANN, B. & FOERSTER, J. (1989) Hämostaseologisches Monitoring in der Intensivtherapie -Untersuchungen mittels Resonanzthrombographie. Anaesthesiologie und Reanimation 14, 219-226
11. HIRSH, J. E., WARKENTIN, T. E., RASCHKE, R., GRANGER, C., OHMANN, E. M. & DALEN, J. E. (1998) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114 (Suppl. 5), 489-510
12. HOLMER, E., KURACHI, K. & SOEDERSTROEM, G. (1981) The molecular-weight dependency of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa. factor XIa. factor XIIa and kallikrein by antithrombin. Biochemical Journal 193, 395-400
13. JACOBS, C., GREBE, S., KIETZMANN, M. & MISCHKE, R. (1999) Pharmakokinetik des unfraktionierten Heparins Liquemin® beim Hund nach intravenöser und subkutaner Injektion basierend auf der Heparinaktivität. Deutsche Tierärztliche Wochenschrift 106, 478-481
14. KANDROTAS, R. J. (1992) Heparin pharmacokinetics and pharmacodynamics. Clinical Pharmucokinetics 22, 359-374
15. KARGES, H. E., FUNK, K. A. & RONNEBERGER, H. (1994) Activity of coagulation and fibrinolysis parameters in animals. Arzneimittel-Forscluaix/Drug Research 44(1), 793-797
16. KITCHEN, S. & PRESTON, F. E. (1996) The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thrombosis and Haemostasis 75, 734-739
17. LEVINE, M. N., HIRSH, J., GENT, M., TURPIE, A. G., CRUICKSHANK, M., WEITZ, J., ANDERSON, D & JOHNSON, M. (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Archives of Internal Medicine 154, 49-56.
18. LUTZE, G. & KUTSCHMANN, K. (1985) Gerinnungsanalytische Untersuchungen bei klinisch gesunden Hunden. Monatshefte für Veterinärmedizin 40, 844-846
19. MATTHIAS, F. R. & DITTER, H. (1984) Prophylaxe und Therapie tiefer Venenthrombosen mit Heparin - speziell in der Chirurgie tiefer Venenthrombosen. Folia Angiologica 32, 1-3
20. POLLER, L., THOMSON, J. M. & TABERNER, D. A. (1989) Use of the activated partial thromhoplastin time for monitoring heparin therapy: problems and possible solutions. Ricerca in Clinica e in Laboratoriti 19, 363-370
21. ROSBOROUGH, T. K. (1997) Comparison of anti-factor Xa hepartin activity and activated partial thromboplastin time in 2.773 plasma samples from unfractionaled heparin-treated patients. American Journal of Clinical Pathology 108, 662-668
22. SHAPIRO, G. A., HUNTZINGER, S. W. & WILSON, J. E. (1977) Variation among commercial activated partial thromboplastin time reagents in response to heparin. American Journal of Clinical Pathology 67, 477-480
23. SHOJANIA, A. M., TETREAULT, J. & TURNBULL, G. (1988) The variations between heparin sensitivity of different lois of activated partial thromboplastin time reagent produced by the same manulacturer. American Journal of Clinical Pathology 89, 19-23
24. UZAN, A., MARIN, J., MARDIGUIAN, J., TRILLOU, M., KIOSSEFF, T. & ROUGEOT, C. (1987) Etude pharmacocinétique comparée, chez le chien, d'une héparine de bas poids moléculaire (Enoxaparine) et de l'héparine, par marquage au soufre 35. Annules Pharmaceutiques Francaises 45, 429-437
25. VAN DEN BESSELAR, A. M. H. P. MEEUWISSE-BRAUN, J. & BERTINA, R. M. (1990) Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thrombosis and Haemostasis 63, 16-23
26. ZIMMERMANN, R., SPRINGER, S., HARENBERG, J., BÜRVENICH, K. & LANG, H. (1987) Überwachung der Heparin- und Fibrinolysetherapie mit Thrombinzeit und aktivierter partieller Thromboplastinzeit. Das Ärztliche Laboratorium 33, 121-126